Abstract The past two decades have seen steady progress in the field of breast cancer genetics as we continually increase our understanding of how tumorigenesis results from damaged DNA. While BRCA1 and BRCA2 have taken center stage as indicators for breast cancer risk, we continue to identify other susceptibility genes and genomic regions, ever increasing our comprehension of breast cancer etiology. Through genome-wide association studies (GWAS), the 19p13 locus was found to contribute to breast and ovarian cancer risk. This region harbors a gene called C19orf62 whose protein has been reported to be a pivotal component in DNA damage repair. In this study, complete sequencing was performed to screen for deleterious mutations in the C19orf62 gene. In our cohort of 110 familial and 144 nonfamilial African-American breast cancer female patients, we identified 35 DNA sequence variants, including four missense variants, which appeared unlikely to be disease-causing. We did not detect deleterious frameshift truncating or nonsense mutations in this cohort. Our findings suggest that germline deleterious mutations in C19orf62 should be rare or absent in familial and nonfamilial breast cancer women. However, the possibility that mutations in C19orf62 contribute to breast cancer risk warrants further studies in large diverse populations.
Introduction
Breast cancer is a heterogeneous disease with genetic and lifestyle/environmental factors implicated in its etiology. The discovery of two breast cancer disease-causing genes, BRCA1 and BRCA2, opened the gates and accelerated the field of genetic research leading to the identification of other breast cancer susceptibility genes, including TP53, PTEN, CHEK2, ATM, BRIP1, PALB2, among others. In addition, mounting evidence from genome-wide association studies (GWAS) has suggested that some genomic loci may confer risk of breast cancer, such as 1p11.2, 2q35, 3p24, 5q11.2, 6q22.33, 6q25.1, 8q24.21, 10q26.13, 11p15.5, 16q12.1, 17q23, among others [1, 2] . Recently, one GWAS identified that common variants on 19p13 were associated with ovarian cancer [3] , while another GWAS pointed out that the same locus could modify the risk of breast cancer in BRCA1 mutation carriers and was associated with susceptibility to ER-negative breast cancer [4] .
The genomic region, 19p13, harbors an eight-exon gene C19orf62 which is also known as BABAM1/HSPC142/ NBA1/MERIT40. This gene spans about 12 kb in the human genome, and encodes a 329-residue protein MERIT40. MERIT40 was recently identified as playing an important role in DNA damage repair and checkpoint control by maintaining the integrity and stability of BRCA1-A complex [5] [6] [7] [8] [9] . The central region (amino acids 90-192) was predicted to possess a von Willebrand factor A (vWA) domain, and amino acids 93-320 was proposed to be an evolutionarily conserved, or unchanged, region over time. In addition, it has been reported that residues 310-314 were essential for ionizing radiation-induced foci (IRIF) formation whereas amino acids 317-321 turned out to be dispensable [5] . Together with the aforementioned genetic findings, the biological evidence supports that C19orf16 might be a plausible breast cancer susceptibility gene.
To evaluate the role of C19orf62 in breast cancer risk, we performed germline mutational analysis by direct sequencing in 254 African-American breast cancer female patients and 262 African-American noncancer controls, with the purpose of looking for pathogenic mutations.
Materials and methods

Study subjects
A total of 273 African-American women with breast cancer, diagnosed at the Cancer Risk Clinic at the University of Chicago, Chicago, from 1993 to 2008, participated in this study. Their family history of breast and/or ovarian cancer, age of onset, along with other clinical characteristics was documented in detail by physicians. We did not base our selection of participants on whether they had a family history, or early age onset, of breast and/or ovarian cancer, so as not to introduce bias with the purpose of achieving a broader understanding of the mutation spectrum in both familial and nonfamilial breast cancer patients. Nineteen breast cancer cases who previously tested positive for BRCA1/2 were excluded; the remaining 254 breast cancer patients consisted of 19 patients with strong family history (more than two first-and/or seconddegree relatives affected by breast and/or ovarian cancer, FDR ? SDR n C 3; age of onset = 45.8 ± 10.9 years [mean ± SD]); 25 patients with moderate family history (FDR ? SDR n = 2; age of onset = 44.6 ± 7.4 years); 66 patients with weak family history (FDR ? SDR n = 1; age of onset = 44.8 ± 9.7 years); and 144 nonfamilial or sporadic breast cancer cases (age of onset = 43.7 ± 10.0 years). In an attempt to explore the frequencies of nonsynonymous/missense variants in the cancer-free normal population, a set of 262 African-American female controls who did not have breast cancer were further sequenced. Informed consents were obtained from all the participants before collecting blood samples. This study was approved by the Institutional Review Board at the University of Chicago.
Mutation identification by sequencing
Genomic DNA was isolated from peripheral blood leukocytes by standard methods and stored at -20°C. Mutational analysis based on the sequenced traces was successfully performed in SeqScape v2.6.0 (Applied Biosystems, USA). Due to the four missense variants found in three amplicons (see below), exon 1 and partial 5 0 UTR, exon 2, as well as exons 6 and 7, we sequenced these amplicons in the normal control subjects. The average sequencing success rates for all amplicons were 99.18% in cases and 99.13% in controls.
In silico analysis of nonsynonymous variants
All variants detected in this study were classified according to their variant type as nonsynonymous, synonymous, untranslated-5 0 UTR, untranslated-3 0 UTR, and intronic. Five different computational programs, SIFT (http://sift. jcvi.org/), PolyPhen (http://genetics.bwh.harvard.edu/pph/), Align GVGD (http://agvgd.iarc.fr/), PMUT (http://mmb2. pcb.ub.es:8080/PMut/), and PANTHER (http://www.pan therdb.org/tools/csnpScoreForm.jsp) were carried out for functional predictions of nonsynonymous variants. Furthermore, it is suggested that in silico assessments might tend to be more accurate when concordance between predictions is obtained. For this study, we determined a missense variant to be deleterious, in the circumstance of at least four functional prediction algorithms providing pathological implications.
Nomenclature
The variants found in this study were named according to the GenBank C19orf62 reference sequence NM_001033549 and NP_001028721, following the instructions provided by the HGVS (http://www.hgvs.org). We also checked the nomenclature by Mutalyzer v2.0 (http://www.mutalyzer.nl/ 2.0/).
Results
All the eight exons, exon/intron boundaries, 5 0 UTR and 3 0 UTR of the C19orf 62 gene were successfully sequenced. The details and occurrence of the genetic variants identified by sequencing were listed in ) . We also investigated their occurrences in control subjects. Except for c.320T[G, the remaining three were detectable in normal controls. We performed in silico functional predictions for these four nonsynonymous variants utilizing SIFT, PolyPhen, Align GVGD, PMUT, and PANTHER. We established an evaluation method for determining deleterious variants, namely, a missense variant was defined as deleterious when pathological outputs from at least four prediction algorithms were obtained. Based on this classification setting, c.133G[A and c.320T[G were predicted to be benign, whereas c.343G[A and c.590C[T were likely to be deleterious. However, there was no difference in the prevalence of these four variants between the case and control groups. The Fisher exact test showed a two-sided P = 0.64 (8/254 vs. 11/262) for c.343G[A and c.590C[T only; and a twosided P = 0.83 (10/254 vs. 12/262) for all the four missense variants combined.
Discussion
One in eight women in the United States will develop breast cancer during her lifetime and one of thirty-five will die because of it. It is well known that deleterious mutations within the BRCA1 and BRCA2 genes confer high risks of breast and ovarian cancer, while some moderate-penetrance genes like PTEN, CHEK2, ATM, BRIP1, and PALB2 may contribute to a limited portion of breast cancer risk. Genome-wide association studies from recent years have significantly broadened our current views of breast cancer susceptibility; however, the inherited risks of breast cancer remain unclear for the more than 70% of the breast cancer patients, especially for the nonfamilial/sporadic cases [10, 11] .
The C19orf62 gene is mapped to 19p13, a region recently found to predispose one to breast and/or ovarian cancer. Antoniou et al. performed a GWAS that found five single nucleotide polymorphisms (SNPs) on 19p13 to be associated with breast cancer and in follow-up replication found association in 4,176 affected and 4,202 unaffected BRCA1 mutation carriers [4] . Further investigation on these SNPs also suggested an association with ER-negative and triple-negative breast cancer, where tumors lack expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 Her2/neu). These five SNPs were located in a 200 kb linkage disequilibrium (LD) block harboring NR2F6, USHBP1, C19orf62, ANKLE1 and ABHD8. In addition, two of the SNPs, rs8170 (in C19orf62) and rs2363956 (in ANKLE1), showed no evidence of association with breast cancer risk for BRCA2 mutation carriers (n = 2,486). Bolton et al. conducted a three-phase GWAS of epithelial ovarian cancer (EOC) in more than 10,000 cases and 13,000 controls [3] where rs8170 and rs2363956 were associated with EOC survival and the risk of serious subtype EOCs. Their array comparative genomic hybridization (aCGH) data demonstrated amplification (copy number gain) of the associated region and the expression analysis suggested that C19orf62 but not ANKLE1 was remarkably over-expressed in ovarian cancer cell lines.
The gene product of C19orf62, MERIT40, together with other proteins such as BRCA1, RAP80/UIMC1, AB-RAXA/CCDC98/, BRCC36, and BRCC45/BRE, form the BRCA1-A macrocomplex which was reported to play a crucial role in G2-M checkpoint control, cellular resistance to ionizing radiation, and BRCA1 retention at damageinduced foci [8] . MERIT40 is responsible for the integrity and stability of BRCA1-A complex in order to successfully undertake DNA double-strand breaks (DSBs) recognition and (de)ubiquitination regulation upon DNA damage response [5] [6] [7] 9] .
From these genetic and biological findings identifying C19orf62 as a candidate breast cancer susceptibility gene, we initiated a direct sequencing study to investigate whether mutations in the C19orf62 gene could predispose one to the breast cancer risk. We sequenced all the exons, exon/ intron boundaries, 5 0 UTR and 3 0 UTR of C19orf 62 in 254 African-American women with breast cancer, whether they had a positive family history or early age of onset of breast and/or ovarian cancer. Although no frameshift truncating or nonsense mutation was detected, we were able to identify 35 sequence variants in which four were missense variants (c. notable that Solyom et al. recently sequenced the same gene in 125 familial breast cancer patients in Finland but failed to detect disease-related germline variants in the C19orf62 gene [12] . In line with Solyom et al., our findings support that germline deleterious coding mutations in C19orf62 are rare or absent in familial and nonfamilial breast cancer women. Our study has sufficient power (87%) to detect a deleterious mutation with minor allele frequency of 0.004. Therefore, a frameshift truncating or nonsense mutation, if exists in this gene, may be rarer than 0.004. To capture very rare mutations (\0.001), it will be necessary to carry out sequencing study using a larger sample size. Alternatively, regulatory elements which have generally subtle effect may account for the risk of breast cancer. As of February 2011, there are over 800 GWAS on human complex diseases/traits, but most of the signals have not directly linked to causal variants that lead to amino acid changes. It, therefore, remains to be seen whether common regulatory variants and/or rare coding mutations in C19orf62 or other genes within the same LD block on 19p13 contribute to the breast cancer risk. Furthermore, it will be interesting to explore the possibility of C19orf62 mutations predisposing to other cancers, for instance, ovarian cancer. To date, there exists only two studies including ours reporting the mutational screening results of C19orf62 in breast cancer patients. To fully appreciate the role of C19orf62 in breast cancer susceptibility, mutation spectrum analyses require further investigation in diverse populations including Asians, Africans, Latinos, among others.
